-
公开(公告)号:US20180193315A1
公开(公告)日:2018-07-12
申请号:US15907597
申请日:2018-02-28
申请人: AbbVie Inc.
发明人: Edward A. Kesicki , Arthur F. Kluge , Michael A. Patane , John H. Van Drie, JR. , Ce Wang , Maricel Torrent , Michael L. Curtin , Todd M. Hansen , Rick F. Clark , Robin R. Frey , Zhiqin Ji , Yujia Dai , William J. McClellan , Jane Gong , Gui-dong G. Zhu , Anthony Mastracchio , Michael R. Michaelides , Thomas D. Penning , Chunqiu C. Lai
IPC分类号: A61K31/4184 , C07D403/06 , C07D498/10 , A61K31/4439 , A61K31/423 , C07D405/06 , C07D409/06 , C07D403/12 , C07D413/14 , C07D235/02 , C07D401/12 , C07D407/12 , C07D409/12 , C07D413/04 , C07D413/12 , C07D417/04 , C07D417/12 , C07D263/52 , C07D491/107 , C07D493/10 , C07D495/10 , C07D401/06
CPC分类号: A61K31/4184 , A61K31/423 , A61K31/4439 , C07D235/02 , C07D263/52 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/06 , C07D407/12 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D491/107 , C07D493/10 , C07D495/10 , C07D498/10
摘要: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1-Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
-
公开(公告)号:US20180071262A1
公开(公告)日:2018-03-15
申请号:US15727220
申请日:2017-10-06
申请人: AbbVie Inc.
发明人: Edward A. Kesicki , Arthur F. Kluge , Michael A. Patane , John H. Van Drie, JR. , Ce Wang , Maricel Torrent , Michael L. Curtin , Todd M. Hansen , Rick F. Clark , Robin R. Frey , Zhiqin Ji , Yujia Dai , William J. McClellan , Jane Gong , Gui-dong G. Zhu , Anthony Mastracchio , Michael R. Michaelides , Thomas D. Penning , Chunqiu C. Lai
IPC分类号: A61K31/4184 , C07D498/10 , C07D403/06 , C07D493/10 , C07D491/107 , C07D263/52 , C07D417/12 , C07D417/04 , C07D413/12 , C07D413/04 , C07D409/12 , C07D407/12 , C07D401/12 , C07D235/02 , C07D413/14 , C07D403/12 , C07D409/06 , C07D405/06 , A61K31/423 , A61K31/4439 , C07D401/06 , C07D495/10
CPC分类号: A61K31/4184 , A61K31/423 , A61K31/4439 , C07D235/02 , C07D263/52 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/06 , C07D407/12 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D491/107 , C07D493/10 , C07D495/10 , C07D498/10
摘要: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
-
公开(公告)号:US20160235716A1
公开(公告)日:2016-08-18
申请号:US14857419
申请日:2015-09-17
申请人: ABBVIE INC.
发明人: Edward A. Kesicki , Arthur F. Kluge , Michael A. Patane , John H. Van Drie, JR. , Ce Wang , Maricel Torrent , Michael L. Curtin , Todd M. Hansen , Rick F. Clark , Robin R. Frey , Zhiqin Ji , Yujia Dai , William J. McClellan , Jane Gong , Gui-dong G. Zhu , Anthony Mastracchio , Michael R. Michaelides , Thomas D. Penning , Chunqiu C. Lai
IPC分类号: A61K31/4184 , C07D403/06 , C07D405/06 , A61K31/423 , C07D401/06 , A61K31/4439 , C07D263/52 , C07D235/02 , C07D409/06
CPC分类号: A61K31/4184 , A61K31/423 , A61K31/4439 , C07D235/02 , C07D263/52 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/06 , C07D407/12 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D491/107 , C07D493/10 , C07D495/10 , C07D498/10
摘要: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1- - - -Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
摘要翻译: 具有式(IX)结构的化合物或其立体异构体,互变异构体或其药学上可接受的盐,其中R1,R2a,R2b,R3a,R3b,R4a,R4b,Q1- - -Q2,R6,R7,A,B ,W,x和y如本文所定义并提供。 还提供了包含这些化合物的药物组合物和通过施用这些化合物治疗各种HAT相关病症或疾病(包括癌症)的方法。
-
-